

SPONSOR-MINDED EARLY CLINICAL DEVELOPMENT

Keelira is an early clinical development partner supporting biotechnology and pharmaceutical companies in the design and delivery of Phase I and Phase II programs across Europe.

Built within Ryvu Therapeutics, Keelira combines strategic advisory, clinical execution and translational sciences within one accountable development model.

FROM DEVELOPMENT STRATEGY TO DECISION-READY EVIDENCE

Set the development direction

Shape the clinical, regulatory, CMC and translational strategy around the next critical milestone.

Lead execution

Coordinate countries, sites, investigators, vendors and study operations through one accountable execution model.

Deliver the evidence

Generate the clinical and translational package required for the next development, financing or partnering decision.

Value by Design

Keelira designs backwards from the next value inflection point – defining the evidence, sequencing and execution required to reach it.

- align scientific and operational priorities around the asset;
- protect critical timelines and capital;
- generate decision-ready evidence;
- strengthen development, financing and partnering options.

”

Every clinical milestone should strengthen the asset. Keelira brings strategy, evidence and execution together to help sponsors move programs forward with greater control over timelines, capital and development decisions.

Kamil Sitarz, PhD, MBA
General Manager



WHY KEELIRA

A development model built around sponsor priorities, execution ownership and European delivery.

Sponsor-side expertise

Built within Ryvu Therapeutics, Keelira's model was shaped through the development of complex Phase I and Phase II programs from the perspective of the company owning the asset. Deep execution experience in oncology and hemato-oncology, Phase I-II.

CRO Plus model

The strategic depth of a development consultancy, the delivery capability of a CRO and the asset-level perspective of an in-house team – integrated within one accountable model.

Europe under one execution model

Coordinated delivery across all 27 EU member states and selected non-EU European markets, supported by local regulatory, operational and site expertise.

Site activation
up to **2-3x** faster
than industry
benchmark

Forecast accuracy
nearly **4x** tighter
than standard CRO
delivery

60+ days saved
on average
per CTA vs. CRO
benchmark

Established European site relationships

70+
Poland

20+
Spain


15+
Italy

15+
France

+ Germany, UK, Hungary, Romania, Bulgaria
& broader CEE

Local expertise in each market.

One accountable execution model across the program.



Turn your next milestone into a value inflection point.

Contact the Keelira team to discuss the evidence, alignment and execution required to move your program forward.

 www.keelira.com

 contact@keelira.com